ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update

ImageneBio, Inc. (NASDAQ:IMA) saw a significant decrease in short interest in August. As of August 14th, there was short interest totaling 49,297 shares, a decrease of 87.2% from the July 30th total of 384,525 shares. Based on an average daily volume of 9,956 shares, the days-to-cover ratio is presently 5.0 days. Currently, 0.4% of the shares of the company are sold short.

ImageneBio News Summary

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: Analysts set a $30.00 price target for ImageneBio, implying considerable upside from the recent price near $5.55. The target could support investor sentiment, although the report does not identify a new business or clinical catalyst. Analysts Set ImageneBio, Inc. Price Target at $30.00
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $28.00 price target. Multiple estimates issued by the firm reinforce a bullish valuation view despite projected losses.
• Positive Sentiment: Reported short interest fell 87.2% to 49,297 shares as of August 14 from 384,525 shares at the end of July. Short interest represented approximately 0.4% of shares outstanding, potentially reducing near-term short-selling pressure.
• Neutral Sentiment: A separate report lists short interest at zero shares as of August 25, unchanged from zero on August 10. Because this conflicts with the other short-interest figures and includes an invalid percentage change, investors should treat the data cautiously. The stock’s very low recent trading volume also limits the significance of short-interest trends.
• Negative Sentiment: HC Wainwright expects ImageneBio to remain deeply unprofitable, forecasting EPS of -$3.57 for fiscal 2026 and -$5.48 for fiscal 2027, with losses continuing through fiscal 2030. These projections highlight ongoing financing and execution risks for the biotechnology company.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IMA. Stonepine Capital Management LLC bought a new stake in shares of ImageneBio during the 2nd quarter worth $539,044,000. Trails Edge Capital Partners LP purchased a new stake in shares of ImageneBio during the second quarter valued at $1,663,824,000. Hsbc Holdings PLC acquired a new position in shares of ImageneBio in the 2nd quarter valued at $208,000. Cable Car Capital LP acquired a new position in shares of ImageneBio in the 2nd quarter valued at $4,611,000. Finally, Blue Owl Capital Holdings LP purchased a new position in ImageneBio in the 2nd quarter worth about $5,414,000. Institutional investors own 75.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMA. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th. HC Wainwright started coverage on ImageneBio in a research report on Friday, August 21st. They issued a “buy” rating and a $28.00 target price for the company. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $29.00.

ImageneBio Stock Performance

Shares of NASDAQ:IMA remained flat at $5.55 during trading hours on Wednesday. 4,740 shares of the stock traded hands, compared to its average volume of 148,203. ImageneBio has a one year low of $3.94 and a one year high of $13.98. The company’s 50 day simple moving average is $5.79 and its two-hundred day simple moving average is $5.83. The stock has a market cap of $62.99 million, a P/E ratio of -1.21 and a beta of 0.76.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.27. Analysts expect that ImageneBio will post -3.23 EPS for the current fiscal year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.